Compare DexCom, Inc. (DXCM) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Snowflake Inc — how do they compare? DexCom, Inc. trades at $77.15 (market cap $28.06B), while Snowflake Inc trades at $274.12 (market cap $94.23B). The key difference: Snowflake Inc is far larger — about 3.4× DexCom, Inc.'s market cap, and Snowflake Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | SNOW | |
|---|---|---|
Market Cap | $28.06B | $94.23B |
Sector | Health | Technology |
52-Week High | $89.53 | $280.16 |
52-Week Low | $54.84 | $121.11 |
Enterprise Value | $27.03B | $94.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Snowflake (SNOW) trades at $273.26, down 0.97% on the day, with strong technical momentum showing a bullish moving average signal. The company continues to deliver impressive revenue growth, reaching $3.63 billion in 2025, while maintaining consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 80.77% buy ratings and a $297.35 consensus price target, representing 8.8% upside potential from current levels.
Despite strong growth fundamentals, Snowflake faces significant profitability challenges with a -23.79% net margin and negative ROE of -55.07%. The stock trades at premium valuations (P/S 18.4x, P/B 48.6x) while burning cash, creating execution risk. However, accelerating AI Data Cloud adoption and CEO's ambitious $184 billion market cap target by 2033 provide long-term growth catalysts if the company can achieve sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
